Rieckmann K H, Yeo A E, Davis D R, Hutton D C, Wheatley P F, Simpson R
Army Malaria Research Unit, University of Sydney, Ingleburn, NSW.
Med J Aust. 1993 Apr 5;158(7):446-9. doi: 10.5694/j.1326-5377.1993.tb137571.x.
To assess the value of various drug regimens for malaria prophylaxis under circumstances where dapsone and pyrimethamine (combined as Maloprim) and chloroquine, followed by the 14-day primaquine eradication course, were no longer effective in protecting military personnel against falciparum and vivax malaria.
DESIGN, SETTING AND PARTICIPANTS: Various drug regimens given to four groups of healthy male members of the Australian Army during training exercises in malarious countries.
Four groups of soldiers were given different regimens for 3-12 weeks: Group 1--mefloquine (250 mg weekly); Group 2--doxycycline (100 mg daily); Group 3--doxycycline (100 mg daily) and primaquine (7.5 mg daily); and Group 4--doxycycline (50 mg daily) and chloroquine (300 mg weekly). Except in Group 3, each of these regimens was followed by a 7.5 mg dose of primaquine three times a day for two weeks.
The proportion of participants in the various prophylactic drug groups who developed falciparum or vivax malaria during or after the intervention.
Group 1: 40 men receiving mefloquine were all protected against falciparum malaria but four (10%) developed vivax malaria. These results were not statistically different from those obtained for either falciparum (P = 0.28) or vivax (P = 0.36) malaria in the control group of 64 men receiving Maloprim and chloroquine. Group 2: 60 men receiving doxycycline (no control group) were all protected against falciparum malaria but two developed vivax malaria. Group 3: 124 men, of whom 55 received doxycycline and 69 primaquine in addition to doxycycline, were all protected against falciparum malaria. However, 13 men taking only doxycycline developed vivax malaria two to three weeks after prophylaxis, whereas no vivax infections were observed in the men taking the drug combination (P = 0.0001). Group 4: no malaria infections were observed in 125 men receiving doxycycline and chloroquine for 13 weeks, probably because of the low prevalence of malaria in the training area.
These studies confirm that doxycycline is very effective in preventing falciparum malaria and, for the first time, also suggest that doxycycline used in combination with small doses of primaquine may prevent (not only suppress) vivax malaria. If further studies confirm these findings, the use of such a drug combination would reduce the incidence of both vivax and falciparum malaria in returning travellers. For individuals with a high risk of exposure to malaria, it would also forestall the need to take the bothersome primaquine eradication course.
在氨苯砜和乙胺嘧啶(合称为疟防片)以及氯喹,随后进行14天伯氨喹根治疗程,对军事人员预防恶性疟和间日疟不再有效的情况下,评估各种药物方案预防疟疾的价值。
设计、背景和参与者:在疟疾流行国家的训练演习期间,对澳大利亚陆军的四组健康男性成员给予各种药物方案。
四组士兵接受不同方案治疗3至12周:第1组——甲氟喹(每周250毫克);第2组——多西环素(每日100毫克);第3组——多西环素(每日100毫克)和伯氨喹(每日7.5毫克);第4组——多西环素(每日50毫克)和氯喹(每周300毫克)。除第3组外,这些方案之后均为每日三次服用7.5毫克伯氨喹,共两周。
各预防用药组在干预期间或之后发生恶性疟或间日疟的参与者比例。
第1组:40名服用甲氟喹的男性均受到保护,未感染恶性疟,但有4人(10%)感染间日疟。这些结果与接受疟防片和氯喹的64名男性对照组中恶性疟(P = 0.28)或间日疟(P = 0.36)的结果无统计学差异。第2组:60名服用多西环素的男性(无对照组)均受到保护,未感染恶性疟,但有2人感染间日疟。第3组:124名男性,其中55人服用多西环素,69人除服用多西环素外还服用伯氨喹,均受到保护,未感染恶性疟。然而,仅服用多西环素的13名男性在预防后两至三周感染间日疟,而服用联合用药的男性未观察到间日疟感染(P = 0.0001)。第4组:125名服用多西环素和氯喹13周的男性未观察到疟疾感染,可能是因为训练地区疟疾流行率低。
这些研究证实多西环素在预防恶性疟方面非常有效,并且首次表明小剂量多西环素与伯氨喹联合使用可能预防(不仅是抑制)间日疟。如果进一步研究证实这些发现,使用这种联合用药将降低回国旅行者中恶性疟和间日疟的发病率。对于有高疟疾暴露风险的个体,这也将避免服用麻烦的伯氨喹根治疗程的必要性。